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and are associated with poor oncologic outcomes. These data, however, are based on single institution studies and it is unknown if abnormal preoperative lab values are associated with postoperative complication rates. We sought to characterize abnormal lab values suggestive of paraneoplastic syndromes in patients undergoing surgery for RCC and evaluate their association with postoperative complications.
METHODS: Using the National Surgical Quality Improvement Program (NSQIP) database, we identified all patients having surgery for RCC from [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . We queried Participant User Files with ICD-9 codes for RCC (189.00) and CPT codes for partial or radical nephrectomy (50220, 50225, 50230, 50240, 50543, 50545, 50546) selecting localized disease. We identified abnormal preoperative lab values consistent with paraneoplastic syndromes and categorized renal function by chronic kidney disease (CKD) stage. Normal lab reference ranges were defined using data from the National Library of Medicine where ranges delimit 2 standard deviations (SD) of the mean value. We used logistic regression to test if abnormal preoperative lab values were associated with postoperative complications, including postoperative transfusion, readmission and death. We extended the normal range of lab values to 3SD of the mean for a sensitivity analysis.
RESULTS: A total of 12,986 patients were identified. At least 1 lab abnormality suggestive of a paraneoplastic syndrome was identified in 46% of patients (Table 1) INTRODUCTION AND OBJECTIVES: Both the physical and financial burdens of urinary tract infections (UTIs) are staggering. In the U.S. alone, UTIs result in an estimated societal cost of $5.1 billion. UTIs are primarily caused by uropathogenic Escherichia coli (UPEC) and 1 in 40 women experience chronic UTIs during their lifetime. Women experiencing at least two UTIs per year are often given antibiotics prophylactically. As anticipated, the rates of resistance to these antibiotics in UPEC strains have steadily risen over the past few decades, highlighting the need for new antibiotic scaffolds and therapeutic strategies to treat UTIs. Iron, an essential nutrient used as a co-factor in many biological processes, is restricted in the host environment. Notably, the primary site of UPEC infection, the bladder, has dramatically lower iron levels than the sera. It is not surprising then that UPEC strains deficient in iron acquisition are attenuated. Based on the requirement of iron for full virulence of UPEC and the need for new antibiotic drug scaffolds, the objective of this study was to identify novel natural products that inhibit wildtype UPEC growth in low iron conditions. METHODS: To identify novel scaffolds and validate bacterial iron acquisition as a viable therapeutic target, we screened 33,000 marine microbial-derived natural product extracts (NPEs) against an unmodified UPEC clinical isolate. This ensured that active hits are not susceptible to Gram-negative efflux pumps. The NPEs were collected from the supernatants of marine bacteria as complex mixtures. To identify the structures of the active molecules, marine bacteria were cultured on a large scale and pure molecules were isolated from the NPEs using column chromatography and HPLC. The structures were elucidated using high-resolution mass spectrometry and 2-D NMR.
RESULTS: We identified 204 NPEs that reduce wildtype UPEC growth in low iron by over 90% without chelating iron or impacting bacterial viability in iron-replete medium. From these hits, we have purified a novel family of cyclic natural products that inhibit bacterial growth at nanomolar concentrations. Preliminary data suggest that these small molecules are interfering with iron acquisition machinery.
CONCLUSIONS: These exciting data provide the foundation for exploring the structure-activity relationships of these compounds with their bacterial targets, which will inform the development of antimicrobial therapies that target iron homeostasis in UPEC and other Gramnegative bacteria. Prior work has demonstrated induction of urine and serum IL-6 in pyelonephritis and renal scarring. IL-6 has been linked to antimicrobial peptide (AMP) production in other organs via Stat3 phosphorylation on Tyr705. As a result, we sought to evaluate the potential role of IL-6/Stat3 induced signaling on urothelial AMP expression and UTI susceptibility.
METHODS: We infected 6 week old female C57BL/6J or C3H/ HeOuJ mice transurethrally with UPEC and measured IL-6, phosphorylated (p-)Stat3, and AMP expression by ELISA, qRT-PCR, Western blotting, and immunofluorescence microscopy. The requirement for Lipopolysaccharide (Lps) / Toll-like receptor 4 (Tlr4) signaling was established using Lps-hyporesponsive C3H/HeJ mice, compared to C3H/HeOuJ Lps-sensitive controls. We evaluated the roles of IL-6 in Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY âp-Stat3, AMP production, and UPEC clearance using IL-6 neutralizing antibody and IL-6 knock out (KO) mice. We determined the contribution of Stat3 to AMP production via tamoxifen-inducible Stat3 conditional KO mice. We measured bacterial burden by serial plating on LB agar. Results were evaluated by Mann-Whitney U test with p <0.05 being significant. RESULTS: Upon UPEC infection, we observed a time dependent induction of urinary IL-6 secretion and bladder p-Stat3. Sustained expression of IL-6 and p-Stat3 required intact Tlr4 signaling. P-Stat3 localized to the nuclei of infected bladder urothelium. Bladder AMP mRNA levels increased following peak IL-6 secretion and p-Stat3. IL-6 KO mice exhibited absent urothelial pStat3 and severely blunted AMP mRNA induction following experimental UTI, leading to impaired UPEC clearance. Conversely, intraperitoneal administration of recombinant IL-6 induced bladder p-Stat3 and AMP expression in the absence of infection. Conditional Stat3 deletion reduced bladder AMP mRNA levels at baseline and following experimental UTI. IL-6 neutralizing antibody reduced p-Stat3 levels in C3H/HeOuJ mice, with increased renal UPEC colonization and pyelonephritis severity.
CONCLUSIONS: IL-6 is both necessary and sufficient for urothelial p-Stat3 and AMP transcription, and genetic or acquired IL-6 deficiency leads to increased UTI susceptibility. This implicates IL-6 and Stat3 as master regulators of urothelial AMP transcription in states of sterility and infection. Therapeutic manipulation of the IL-6/Stat3 axis provides a mechanism to alter AMP expression to treat and even prevent UTI.
Source of Funding: SPU 2016 research grant; K08 grant DK102594 from NIDDK
PD12-03 NORMAL PERINEAL MICROBIOME IN PREPUBERTAL FEMALES WITH DYSBIOSIS IF RECURRENT URINARY TRACT INFECTIONS
Christina Ching*, Elizabeth Lucas, Shareef Dabdoub, Purnima Kumar, Sheryl Justice, Columbus, OH INTRODUCTION AND OBJECTIVES: Specific microbial signatures exist in the body to regulate external pathogens. While prior work has focused on the role of the adult genitourinary microbiome in urinary tract health, little research investigates the normal pediatric perineal microbiome and aberrations related to urinary tract infections (UTIs). We strove to define the genitourinary microbiome in the normal developing prepubertal female child and compared this to a small cohort of children with recurrent UTIs.
METHODS: After IRB approval, we consented healthy females at pediatric well-child visits to participate. Children were divided into 4 groups of significant developmental milestones: 1) 0-3 week old newborns; 2) 5-9 month old infants transitioning to solid foods; 3) 3-5 year old toddlers undergoing toilet training; and 4) 9-12 year old premenstrual girls. We also enrolled girls from the urology clinic with a history of UTIs (>50,000 colony forming units) who have been off antibiotics >1 month. Four swabs were taken on each patient: 1) genitourinary (urethral/vaginal introitus); 2) perirectal; 3) periauricular; 4) oral. Next generation 16S rRNA sequencing was performed to identify age and location of specific microbial signatures as well as a signature associated with recurrent UTIs.
RESULTS: A total of 40 patients were recruited: a) 13 newborns; b) 6 infants; c) 13 toddlers; d) 6 premenstrual girls; and e) 2 recurrent UTIs. Children with recurrent UTI were 15 months and 2 years old. There was a clear evolution of the perirectal and genitourinary microbiomes with age, showing divergence at 5-9 months of age. The newborn group had the tightest clustering of bacteria between perirectal and genitourinary microbiomes. Those with recurrent UTI fall outside of any age group clustering let alone their specific age group (Figure 1) . CONCLUSIONS: We are the first to describe the normal prepubertal microbiome. There is a clear divergence and personalization of perirectal and genitourinary microbiomes as early as 5-9 months of age. Likely the tight clustering of newborn perirectal and genitourinary microbiome is a result of the maternal genitourinary microbiome. Children with recurrent UTIs have a dysbiosis of their perineal microbiome compared to children without. This could represent a target of UTI prevention and/or treatment. Yan Liu, Ellen Shapiro, Herbert Lepor, Xue-Ru Wu*, New York, NY INTRODUCTION AND OBJECTIVES: Leukotriene B4 (LTB4), a dihydroxy fatty acid derived from arachidonic acid, acts as a chemoattractant in non-urothelial tissues and plays a role in innate host defenses. However, virtually nothing is known about the role or, the lack thereof, of LTB4 in the urinary tract, which is the focus of the present study.
METHODS: Adult wild-type female mice (7-9 weeks) were inoculated via the transurethral route with type 1 piliated cystitis strain UTI89 or pyelonephritis strain CFT073 (10 7 cfu in 20 ml PBS). Urothelial production and urinary secretion of LTB4 was measured by ELISA, and its localization determined by confocal immunofluorescence microscopy. The effects of LTB4 deficiency on UPEC infections were examined by administering the wild-type mice with zileuton, an inhibitor of LTB4 production and by using knockout mice lacking arachidonate 5-lipoxygenase (ALOX5), a key enzyme in LTB4 biosynthesis. The resultant neutrophil infiltration, intracellular bacterial community (IBC) formation and clearance, neutrophil myeloperoxidase (MPO) activity, bacterial colony forming units were assessed under specific conditions and controls.
RESULTS: In the wild-type mice, both UPEC strains UTI89 and CFT073 triggered an 8-fold increase of LTB4 in urothelium over PBS controls 2 hours after inoculation. The urothelial level of LTB4 continued to rise, peaking at 12 hours and subsiding considerably at 24 hours, the two time points coinciding with the accumulation and clearance of IBC, respectively. Urine levels of LTB4 lagged slightly behind that of urothelium, probably reflecting time required for protein secretion. Inhibition of LTB4 by zileuton included in the UPEC inocula e266 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
